14,992 Shares in Solventum Co. (NYSE:SOLV) Purchased by Strategic Financial Concepts LLC

Strategic Financial Concepts LLC purchased a new stake in shares of Solventum Co. (NYSE:SOLV) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,992 shares of the company’s stock, valued at approximately $990,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Worldquant Millennium Advisors LLC increased its stake in Solventum by 373.6% during the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock valued at $3,323,000 after acquiring an additional 37,600 shares during the period. Harbor Capital Advisors Inc. increased its stake in Solventum by 24.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after acquiring an additional 9,333 shares during the period. The Manufacturers Life Insurance Company increased its stake in Solventum by 37.4% during the third quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock valued at $8,217,000 after acquiring an additional 32,051 shares during the period. State Street Corp increased its stake in Solventum by 3.1% during the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after acquiring an additional 185,938 shares during the period. Finally, Forsta AP Fonden bought a new position in Solventum during the fourth quarter valued at about $1,876,000.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SOLV. Morgan Stanley upped their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Mizuho began coverage on Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective on the stock. Finally, Piper Sandler upped their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $68.29.

Solventum Price Performance

NYSE SOLV opened at $73.57 on Wednesday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The stock’s 50 day simple moving average is $70.45 and its 200 day simple moving average is $68.20. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.